Industry News
Biotechnology Industry News

Roche may have scrapped work on a…
Roche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune diseases.
Royalty Pharma has secured a stake…
Royalty Pharma has secured a stake in another transthyretin-mediated amyloidosis drug, this time paying $125 million upfront to Neurimmune for a cut of the sales of its AstraZeneca-partnered med.
A phase 2 study of Celldex’s…
A phase 2 study of Celldex’s barzolvolimab in a chronic skin disease has missed its primary endpoint, driving the biotech to end development in the indication and raising doubts about an upcoming eczema readout.
A rare disease startup with a…
A rare disease startup with a mission to repurpose proven drugs has licensed a Chinese formulation of a well-known medicine and set its sights on a $50 million fundraise.
A group of 61 biopharma companies,…
A group of 61 biopharma companies, executives and investors has filed an amicus brief in support of the FDA in an ongoing case brought by Louisiana meant to remove access to the abortion pill mifepristone.
Crystalys Therapeutics has raised…
Crystalys Therapeutics has raised $130 million in series B financing to advance the development of its gout drug dotinurad and prepare for a potential commercial launch.
For years, as Big Pharma poured…
For years, as Big Pharma poured billions into ADCs, Novartis CEO Vas Narasimhan notably stayed on the sidelines. Asked by Fierce during Novartis’ Q2 earnings call, Narasimhan explained why he is ending that holdout with
Jupiter Neurosciences will pay…
Jupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.
A phase 2 study of Agios…
A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase activator has failed to support continued development in sickle cell disease, leading the company to ax an indication for the second time in two months.
Novartis has dropped a phase…
Novartis has dropped a phase 2-stage radioligand therapy after the candidate disappointed in the clinic.
Lupin has spun out two…
Lupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise cash for further development. Kaveri’s programs hit targets pursued by major drugmakers including AstraZeneca, Bayer
Axiom Biosciences intends to…
Axiom Biosciences intends to pursue an IPO on the Hong Kong Stock Exchange (HKEX) followed by a co-listing on the Nasdaq—a strategy the company claims it's the first U.S. biotech to use.
A phase 3 trial of Kolon…
A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on determining the next
Scribe Therapeutics has put its…
Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.
Bristol Myers Squibb has entered…
Bristol Myers Squibb has entered into an expanded collaboration with Nvidia to create the biggest supercomputer for drug R&D, according to the announcement.
Latigo Biotherapeutics is…
Latigo Biotherapeutics is preparing to go public in order to bankroll the development of its clinical-stage pipeline of non-opioid pain management drugs.
Geopolitical uncertainty has…
Geopolitical uncertainty has continued to “chill” IPO sentiment among British biotechs, an industry leader has told Fierce, even as the sector saw second-quarter venture capital funding reach a five-year high.
After Eli Lilly dived into the…
After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.
Another biotech is squeezing into…
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperwork with the Securities and Exchange
Another biotech is squeezing into…
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperwork with the Securities and Exchange

